Once validated in vivo studies, our bioengineering strategy, leveraging the α-secretase-dependent cleavage of APP, precludes the amyloidogenic pathway of Aβ generation and, at the same time, increases the production of sAPPα; thus, it could be potentially used as a new strategy to delay or revert the pathological effects in AD. Here, APP is linked to Alzheimer disease.